Amundi Raises Stock Position in The Cooper Companies, Inc. $COO

Key Points

• Amundi increased its Cooper Companies stake by 72% in the second quarter, adding 592,746 shares to own 1.42 million shares worth approximately $101.5 million, or 0.73% of the company.
• Cooper Companies reported quarterly adjusted EPS of $1.15, slightly above analyst expectations, but revenue of about $1.07 billion fell short of estimates and overall growth was modest.
• The company authorized a $3 billion share-repurchase program, while fiscal 2026 EPS guidance of $4.51–$4.55 came in below the $4.63 analyst consensus. Shares opened at $63.48, down 6.2%, with analysts maintaining an average “Hold” rating and an $81.64 consensus price target.

Amundi boosted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO - Free Report) by 72.0% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,416,095 shares of the medical device company's stock after purchasing an additional 592,746 shares during the quarter. Amundi owned about 0.73% of Cooper Companies worth $101,548,000 at the end of the most recent quarter.

A number of other large investors also recently added to or reduced their stakes in the business. Algert Global LLC bought a new stake in shares of Cooper Companies in the 2nd quarter worth about $7,655,000. BlackRock Inc. bought a new position in shares of Cooper Companies in the 2nd quarter valued at about $1,077,762,000. Heartland Advisors Inc. bought a new position in shares of Cooper Companies in the 4th quarter valued at about $15,348,000. Tocqueville Asset Management L.P. purchased a new position in Cooper Companies in the second quarter worth about $1,502,000. Finally, Western Standard LLC purchased a new position in Cooper Companies in the second quarter worth about $5,228,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Cooper Companies Stock Down 6.2%

NASDAQ:COO opened at $63.48 on Thursday. The Cooper Companies, Inc. has a 1-year low of $58.89 and a 1-year high of $89.83. The company has a 50-day moving average of $72.42 and a 200 day moving average of $70.02. The firm has a market cap of $12.38 billion, a PE ratio of 53.80, a price-to-earnings-growth ratio of 1.77 and a beta of 0.82. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.27 and a quick ratio of 0.78.

Cooper Companies (NASDAQ:COO - Get Free Report) last posted its earnings results on Wednesday, September 9th. The medical device company reported $1.15 earnings per share for the quarter, topping analysts' consensus estimates of $1.12 by $0.03. Cooper Companies had a return on equity of 10.88% and a net margin of 5.57%.The company had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. During the same quarter in the prior year, the business earned $0.49 earnings per share. Cooper Companies's revenue was up .5% on a year-over-year basis. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS. As a group, research analysts anticipate that The Cooper Companies, Inc. will post 4.63 EPS for the current fiscal year.

Cooper Companies declared that its board has initiated a share repurchase program on Wednesday, September 9th that allows the company to buyback $3.00 billion in shares. This buyback authorization allows the medical device company to purchase up to 22.7% of its shares through open market purchases. Shares buyback programs are often a sign that the company's management believes its stock is undervalued.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: CooperCompanies reported fiscal Q3 non-GAAP EPS of $1.15, exceeding the $1.11-$1.12 analyst consensus. Revenue reached approximately $1.066 billion, while GAAP EPS was $2.24, helped by a $307.2 million discrete tax benefit from the favorable completion of a U.K. tax examination. CooperCompanies Announces Third Quarter 2026 Results
• Positive Sentiment: Cash generation and capital returns were strong: free cash flow increased 66% to $273 million, and the company repurchased $339.1 million of stock during the quarter. The board also expanded its share-repurchase authorization from $2 billion to $3 billion. CooperCompanies Completes Strategic Review
• Neutral Sentiment: CooperSurgical revenue rose 2% on a reported basis and 3% organically, but CooperVision revenue was unchanged year over year. Overall quarterly revenue growth was only about 1% and fell short of the roughly $1.10 billion consensus estimate.
• Negative Sentiment: Management guided fiscal 2026 non-GAAP EPS to $4.51-$4.55, below the $4.63 analyst consensus, with revenue guidance of $4.229-$4.252 billion. Fourth-quarter EPS guidance of $1.05-$1.09 was also well below the approximately $1.20 expected by analysts. The Cooper Companies Q3 Earnings Metrics
• Negative Sentiment: The strategic review concluded that CooperSurgical will be retained because received offers were not sufficiently attractive. Investors may view this as a missed opportunity to unlock value, particularly amid valuation pressure from a new non-hormonal IUD competitor and fertility-related litigation costs. CooperCompanies Strategic Review and Buyback

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Robert W. Baird cut their target price on Cooper Companies from $98.00 to $85.00 and set an "outperform" rating on the stock in a research report on Friday, June 5th. Weiss Ratings restated a "sell (d)" rating on shares of Cooper Companies in a research report on Friday, September 4th. Piper Sandler set a $86.00 price objective on shares of Cooper Companies and gave the stock an "overweight" rating in a research note on Monday, June 1st. Citigroup reiterated a "neutral" rating and set a $80.00 price objective (up from $76.00) on shares of Cooper Companies in a research report on Thursday, August 13th. Finally, Stifel Nicolaus reduced their target price on shares of Cooper Companies from $95.00 to $85.00 and set a "buy" rating on the stock in a research note on Friday, June 5th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, six have given a Hold rating and three have assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $81.64.

Cooper Companies Profile

Cooper Companies, Inc NASDAQ: COO is a global medical device company headquartered in San Ramon, California. Founded in 1958, the company has grown through strategic acquisitions and organic development to become a major provider of vision care and women's health products. Cooper Companies operates through two primary business segments—CooperVision and CooperSurgical—each serving specialized markets within the healthcare industry.

The CooperVision segment develops, manufactures and markets a broad range of soft contact lenses, as well as related accessories.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.